SUVENPHAR2023-01-012023-03-31 SUVENPHAR2023-01-012023-03-31 SUVENPHAR2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2023-01-012023-03-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2023-01-012023-03-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2023-01-012023-03-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2023-01-012023-03-31in-bse-fin:FourOperatingExpenses03Member SUVENPHAR2023-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2022-04-01 2023-03-31 2023-05-25 2023-05-18 INR Lakhs Yearly 11:30:00 13:20:00 2023-05-25 2023-05-25 true Cash Flow Indirect Declaration of unmodified opinion Single segment Contract Development and Manufacturing 2023-01-01 2023-03-31 Unaudited Consolidated 3693562000.00 113995000.00 3807557000.00 955570000.00 0.00 208769000.00 256021000.00 23086000.00 119583000.00 582419000.00 2145448000.00 1662109000.00 0.00 1662109000.00 407309000.00 15087000.00 422396000.00 0.00 1239713000.00 0.00 0.00 0.00 0.00 1239713000.00 3889000.00 1243602000.00 0.00 0.00 254565000.00 1 4.87 4.87 0.00 0.00 4.87 4.87 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 25th May, 2023. The results for the year ended 31st March, 2023 have been audited and for the quarter ended 31st March , 2023 has been reviewed by our statutory auditors. The statutory auditors of the company have expressed an unmodified opinion on the financials statements for the year ended 31st March ,2023 and issued an unmodified conclusion in respect of limited review for the quarter ended 31st March, 2023. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiarIes Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (w.e.f. 22nd April '2022). 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (02 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (04) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven pharma, Inc . The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary. 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to $35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US $41.555 Mn and a stake valued at US $15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US $20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs. 8) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022. 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2022-04-01 2023-03-31 Audited Consolidated 13403288000.00 463638000.00 13866926000.00 4300788000.00 0.00 -209442000.00 1105109000.00 54363000.00 477324000.00 2541486000.00 8269628000.00 5597298000.00 0.00 5597298000.00 1441020000.00 43375000.00 1484395000.00 0.00 4112903000.00 0.00 0.00 0.00 0.00 4112903000.00 -1864000.00 4111039000.00 0.00 0.00 254565000.00 1 17097278000.00 16.16 16.16 0.00 0.00 16.16 16.16 Manufacturing Expenses 404662000.00 Other Expenses 157667000.00 R & D expenses 20090000.00 Manufacturing Expenses 1762879000.00 Other Expenses 692750000.00 R & D expenses 85857000.00 5841883000.00 1650886000.00 0.00 0.00 791382000.00 0.00 0.00 0.00 1170966000.00 0.00 225000.00 59119000.00 1230310000.00 0.00 32519000.00 9546980000.00 3128105000.00 4189350000.00 1109393000.00 648028000.00 32112000.00 1929000.00 2817000.00 5983629000.00 0.00 998724000.00 10110458000.00 0.00 0.00 19657438000.00 254565000.00 17097278000.00 17351843000.00 17351843000.00 45642000.00 0.00 6998000.00 52640000.00 82951000.00 582346000.00 0.00 0.00 717937000.00 645978000.00 651643000.00 218110000.00 1515731000.00 29527000.00 39461000.00 2939000.00 0.00 1587658000.00 0.00 0.00 2305595000.00 19657438000.00 54363000.00 -293932000.00 0.00 1244652000.00 -204458000.00 -155424000.00 0.00 0.00 0.00 -407259000.00 0.00 -29466000.00 0.00 464599000.00 0.00 -4041000.00 -5994000.00 0.00 -87721000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 575319000.00 6172617000.00 0.00 0.00 -58316000.00 1457914000.00 -147263000.00 4509124000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 720000.00 2857715000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 58316000.00 0.00 850256000.00 0.00 -1948422000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 263680000.00 0.00 3749000.00 2036520000.00 54363000.00 0.00 0.00 -2358312000.00 202390000.00 0.00 202390000.00 445638000.00 648028000.00 4928000.00 -2749000.00 1039000.00 -885000.00